Danielle Antin-Ozerkis, MD
Associate Professor of Medicine (Pulmonary)Cards
Appointments
Additional Titles
Medical Director, Yale ILD Center of Excellence, Pulmonary, Critical Care & Sleep Medicine
Director, Yale ILD Center of Excellence, Pulmonary, Critical Care & Sleep Medicine
Contact Info
Pulmonary, Critical Care & Sleep Medicine
PO Box 208057, 15 York Street
New Haven, CT 06520-8057
United States
Appointments
Additional Titles
Medical Director, Yale ILD Center of Excellence, Pulmonary, Critical Care & Sleep Medicine
Director, Yale ILD Center of Excellence, Pulmonary, Critical Care & Sleep Medicine
Contact Info
Pulmonary, Critical Care & Sleep Medicine
PO Box 208057, 15 York Street
New Haven, CT 06520-8057
United States
Appointments
Additional Titles
Medical Director, Yale ILD Center of Excellence, Pulmonary, Critical Care & Sleep Medicine
Director, Yale ILD Center of Excellence, Pulmonary, Critical Care & Sleep Medicine
Contact Info
Pulmonary, Critical Care & Sleep Medicine
PO Box 208057, 15 York Street
New Haven, CT 06520-8057
United States
About
Titles
Associate Professor of Medicine (Pulmonary)
Medical Director, Yale ILD Center of Excellence, Pulmonary, Critical Care & Sleep Medicine; Director, Yale ILD Center of Excellence, Pulmonary, Critical Care & Sleep Medicine
Biography
Dr. Antin-Ozerkis received her Bachelor’s degree from Princeton University. She went on to complete her medical degree, residency, and fellowship in Pulmonary and Critical Care Medicine at the University of Pennsylvania, where she pursued advanced fellowship training in the evaluation and management of advanced lung disease and lung transplant patients. She came to Yale in 2006. Dr. Antin-Ozerkis is Medical Director of the Yale Interstitial Lung Disease Center of Excellence. Her specific area of clinical expertise is the diagnosis and treatment of interstitial lung diseases (ILD), with a focus on idiopathic pulmonary fibrosis (IPF) and connective tissue disease-associated interstitial lung disease (CTD-ILD). She leads a multidisciplinary group which meets weekly to review patient cases, offering consensus opinions on diagnosis and management. As part of a comprehensive approach to patient care, Yale ILD offers clinical drug trials for patients with IPF and other forms of pulmonary fibrosis. Dr. Antin-Ozerkis is the primary investigator at Yale for these studies. She participates in the Center’s translational research program which is aimed at understanding the mechanisms of pulmonary fibrosis development and progression.
Appointments
Pulmonary, Critical Care & Sleep Medicine
Associate Professor on TermPrimary
Other Departments & Organizations
- Internal Medicine
- Interstitial Lung Disease (ILD) Program
- Pulmonary, Critical Care & Sleep Medicine
- Scleroderma Program
- Winchester Center for Lung Disease
- Yale Medicine
- Yale Ventures
Education & Training
- Fellow
- University of Pennsylvania Health System (2006)
- Resident
- University of Pennsylvania (2002)
- MD
- University of Pennsylvania Medical School (1999)
- BA
- Princeton University (1990)
Research
Research at a Glance
Yale Co-Authors
Publications Timeline
Erica Herzog, MD, PhD
Mridu Gulati, MD
Naftali Kaminski, MD
Robert Homer, MD, PhD
Vaidehi R. Chowdhary, MBBS, MD
Ami Rubinowitz, MD
Publications
2024
INTERACTIONS BETWEEN MITOCHONDRIAL DNA AND TOLL-LIKE RECEPTOR 9 MEDIATES PULMONARY FIBROSIS
LEE C, TRUJILLO G, REGUEIRO-REN A, LIU C, HU B, SUN Y, KHOURY J, KHOURY J, AHANGARI F, ISHIKAWA G, WALIA A, PIVARNIK T, YU S, WOO S, FIORINI V, MCGOVERN J, AL JUMAILY K, SUN H, PENG X, ANTIN-OZERKIS D, SAULER M, KAMINSKI N, HERZOG E. INTERACTIONS BETWEEN MITOCHONDRIAL DNA AND TOLL-LIKE RECEPTOR 9 MEDIATES PULMONARY FIBROSIS. CHEST Journal 2024, 166: a3384-a3386. DOI: 10.1016/j.chest.2024.06.2020.Peer-Reviewed Original ResearchToll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis.
Trujillo G, Regueiro-Ren A, Liu C, Hu B, Sun Y, Ahangari F, Fiorini V, Ishikawa G, Al Jumaily K, Khoury J, McGovern J, Lee C, Peng X, Pivarnik T, Sun H, Walia A, Woo S, Yu S, Antin-Ozerkis D, Sauler M, Kaminski N, Herzog E, Ryu C. Toll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2024 PMID: 39189851, DOI: 10.1164/rccm.202401-0065oc.Peer-Reviewed Original ResearchAltmetricConceptsToll-like receptor 9Model of pulmonary fibrosisIdiopathic pulmonary fibrosisPulmonary fibrosisFibroproliferative responseLung diseaseIdiopathic pulmonary fibrosis cohortsExpression of toll-like receptor 9Toll-like receptor 9 activationTransplant-free survivalExpression of MCP-1Cohort of patientsSlow clinical progressionFibrotic lung diseaseAccelerated disease courseFatal lung diseaseIP-10Pharmacodynamic endpointsPreclinical modelsDisease courseClinical progressionPlasma mtDNAMCP-1Receptor 9Mouse modelBexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial
Lancaster L, Cottin V, Ramaswamy M, Wuyts W, Jenkins R, Scholand M, Kreuter M, Valenzuela C, Ryerson C, Goldin J, Kim G, Jurek M, Decaris M, Clark A, Turner S, Barnes C, Achneck H, Cosgrove G, Lefebvre É, Flaherty K, Baratz D, Ettinger N, Layish D, Epstein M, Veeraraghavan S, Golden J, Ramaswamy M, Bascom R, Lancaster L, Scholand M, Case A, Zaman T, Betensley A, Antin-Ozerkis D, Montessi S, Fernandez E, Boente R, Sager J, Hunninghake G, Gibson K, Srour N, Dhar A, Wuyts W, Wielders P, Veltkamp M, Mostard R, Janssen R, Noordegraaf A, Glaspole I, Corte T, Beckert L, Brockway B, Veale A, Richeldi L, Harari S. Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial. American Journal Of Respiratory And Critical Care Medicine 2024, 210: 424-434. PMID: 38843105, PMCID: PMC11351797, DOI: 10.1164/rccm.202403-0636oc.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTreatment-emergent adverse eventsQuantitative lung fibrosisIdiopathic pulmonary fibrosisPulmonary fibrosisRates of treatment-emergent adverse eventsIncidence of treatment-emergent adverse eventsClinical trialsTreatment of idiopathic pulmonary fibrosisExploratory efficacy endpointsImpaired quality of lifeFibrosis-related biomarkersDose cohortsBackground therapyPlacebo groupTolerability profileOnce-dailyEfficacy endpointPrimary endpointProgressive diseaseExertional dyspneaFVC declineFibrosis biomarkersAdverse eventsIPF therapyLung fibrosisPamrevlumab for Idiopathic Pulmonary Fibrosis
Raghu G, Richeldi L, Fernández Pérez E, De Salvo M, Silva R, Song J, Ogura T, Xu Z, Belloli E, Zhang X, Seid L, Poole L, Bowler S, Corte T, Holmes M, Thien F, Wheatley J, Choi S, Chung M, Jeong S, Kim Y, Lee E, Lee H, Park C, Park J, Park J, Chi-Leung Lam D, Chan M, Lee K, Cao J, Chen J, Chen R, Dai H, Fu X, Liang Z, Luo Q, Shi G, Tong Z, Wang L, Yang S, Yu H, Zhang H, Zhang J, Zhao H, Wang W, Meng Y, Peng H, Ramaswamy M, Hamblin M, Fitzgerald J, Gupta N, Dematte J, Veeraraghavan S, O’Brien T, Luckhardt T, Lancaster L, Kokoszynska M, Ettinger N, Kaelin T, Siddiqi A, Collins B, Scholand M, Antin-Ozerkis D, Hyun K, Harden C, Averill F, Mallea J, Bascom R, Seeram V, Hajari Case A, Britt E, Shea B, Criner G, Gotfried M, Mageto Y, El Bayadi S, Reichner C, Mooney J, Hotchkin D, Abrencillo R, Boente R, Lee J, Betensley A, Jeganathan N, Walia R, Albertson T, Rosas I, Puppala D, Abraham L, Enelow R, Bhatt N, Bandyopadhyay D, Elias P, Bergna M, Garcia G, De Stefano G, Wehbe L, Chirino A, Rojas R, Otaola M, Miranda G, Florenzano M, Silva Orellana R, Glasinovich V, Shangina O, Nikishenkov A, Kuzubova N. Pamrevlumab for Idiopathic Pulmonary Fibrosis. JAMA 2024, 332: 380-389. PMID: 38762797, PMCID: PMC11304118, DOI: 10.1001/jama.2024.8693.Peer-Reviewed Original ResearchCitationsAltmetricConceptsIdiopathic pulmonary fibrosisBaseline to weekPulmonary fibrosisAdverse eventsBetween-group differencesPrimary outcomePhase 3 randomized clinical trialSecondary outcomesTreatment-related adverse eventsProgression of idiopathic pulmonary fibrosisPhase 2 trialAssociated with adverse eventsRate of lung function declineSubstantial adverse eventsAbsolute changeStatistically significant between-group differencesPatient-reported symptomsLung function declineSignificant between-group differencesFollow-up encountersPatient-reported outcomesPlacebo groupAntifibrotic treatmentPamrevlumabClinical trials2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care & Research 2024, 76: 1070-1082. PMID: 38973729, DOI: 10.1002/acr.25347.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSystemic autoimmune rheumatic diseasesInterstitial lung diseasePulmonary function testsAutoimmune rheumatic diseasesMonitoring of interstitial lung diseaseChest radiographyHigh-resolution computed tomography of the chestInterstitial lung disease risk factorsLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeDevelopment of interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansHigh-resolution computed tomographyMonitoring interstitial lung diseasesSurgical lung biopsyIdiopathic inflammatory myopathiesConnective tissue diseaseClinical practice guidelinesWalk test distanceGrading of RecommendationsEvidence-based recommendationsLung biopsy2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis & Rheumatology 2024, 76: 1201-1213. PMID: 38973714, DOI: 10.1002/art.42860.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSystemic autoimmune rheumatic diseasesInterstitial lung diseasePulmonary function testsAutoimmune rheumatic diseasesMonitoring of interstitial lung diseaseChest radiographyHigh-resolution computed tomography of the chestInterstitial lung disease risk factorsLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeDevelopment of interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansHigh-resolution computed tomographyMonitoring interstitial lung diseasesSurgical lung biopsyIdiopathic inflammatory myopathiesConnective tissue diseaseClinical practice guidelinesWalk test distanceGrading of RecommendationsEvidence-based recommendationsLung biopsy2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis & Rheumatology 2024, 76: 1182-1200. PMID: 38978310, DOI: 10.1002/art.42861.Peer-Reviewed Original ResearchCitationsAltmetricConceptsTreatment of interstitial lung diseaseSystemic autoimmune rheumatic diseasesInterstitial lung diseaseAutoimmune rheumatic diseasesLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeProgressive interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansClinical practice guidelinesGrading of RecommendationsEvidence-based recommendationsClinically relevant populationOutcome questionsPractice guidelinesSystematic literature reviewDiseasePhysiciansTreatmentGlucocorticoidTherapyRelevant populationRecommendations2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care & Research 2024, 76: 1051-1069. PMID: 38973731, DOI: 10.1002/acr.25348.Peer-Reviewed Original ResearchCitationsAltmetricConceptsTreatment of interstitial lung diseaseSystemic autoimmune rheumatic diseasesInterstitial lung diseaseAutoimmune rheumatic diseasesLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeProgressive interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansClinical practice guidelinesGrading of RecommendationsEvidence-based recommendationsClinically relevant populationOutcome questionsPractice guidelinesSystematic literature reviewDiseasePhysiciansTreatmentGlucocorticoidTherapyRelevant populationRecommendationsEvaluation of the Contribution of Clinical Parameters for the Diagnosis of Idiopathic Pulmonary Fibrosis by an International Panel of Clinicians
Abecassis C, Pastre J, Hajari Case A, Antin-Ozerkis D, Shifren A, Libre E, Picone C, Johri S, Hindre R, Benattia A, Riviere F, Wemeau L, Ouaknine J, Taverne J, Hamdan A, Ben Dhiab R, Chung J, Dubocage A, Maillard A, King C, Nathan S. Evaluation of the Contribution of Clinical Parameters for the Diagnosis of Idiopathic Pulmonary Fibrosis by an International Panel of Clinicians. 2024, a1766-a1766. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1766.Peer-Reviewed Original ResearchContinued nintedanib treatment in patients with progressive pulmonary fibrosis: data from INBUILD-ON
Bonella F, Wuyts W, Chaudhuri N, Varone F, Antin-Ozerkis D, Song J, Miede C, Dumistracel M, Coeck C, Cottin V. Continued nintedanib treatment in patients with progressive pulmonary fibrosis: data from INBUILD-ON. Pneumologie 2024, 78: s79-s79. DOI: 10.1055/s-0044-1781400.Peer-Reviewed Original ResearchCitations
Clinical Trials
Current Trials
Pathogenic Wnt-beta catenin target genes in macrophages and fibrosis
HIC ID2000024862RoleSub InvestigatorPrimary Completion Date12/31/2023Recruiting Participants
Clinical Care
Overview
Danielle Antin-Ozerkis, MD, specializes in the evaluation and management of advanced lung disease. She is the medical director of the Yale Medicine Interstitial Lung Disease Program and cares for patients with all forms of the disease.
“We look for any signs of connective tissue disease and for possible exposures in the workplace and home (such as birds and mold), all of which can lead to interstitial lung disease,” explains Dr. Antin-Ozerkis. “We have a dedicated multidisciplinary group that meets weekly to discuss patient cases and research. Everything we do keeps the focus on the patient. It is so important to get the diagnosis right, as the correct treatment hinges on this. Sometimes the therapy involves new antifibrotic drugs. Other patients may require immunosuppressive therapy. For some, clinical trials are an option. We also focus on quality of life, exercise, oxygen, nutrition and emotional support.”
An associate professor of medicine (pulmonary) at Yale School of Medicine, Dr. Antin-Ozerkis says she enjoys the complexities of pulmonary medicine and the personalized approach involved in treating it. “I love talking with people and trying to understand the reasons they became ill,” she says. “Each time I can sit with a patient and talk with them about their disease in a way that they haven't heard before makes my work feel worthwhile.”
Clinical Specialties
Fact Sheets
Interstitial Lung Disease (ILD)
Learn More on Yale MedicinePediatric Respiratory Failure
Learn More on Yale MedicineSarcoidosis
Learn More on Yale MedicineChronic Obstructive Pulmonary Disease (COPD)
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews & Links
News
- November 27, 2023
Winchester Center for Lung Disease is Flourishing Since Opening in 2021
- March 27, 2023
Diagnosing Pulmonary Hypertension Through Non-invasive Methods
- March 21, 2023
Department of Internal Medicine Promotions and Reappointments
- September 08, 2022
Yale Physicians Explore Pulmonary Fibrosis and Related Comorbidities
Get In Touch
Contacts
Pulmonary, Critical Care & Sleep Medicine
PO Box 208057, 15 York Street
New Haven, CT 06520-8057
United States
Administrative Support
Locations
Academic Office
Academic Office
Lippard Laboratory of Clinical Investigation (LLCI)
15 York Street, Ste 101B
New Haven, CT 06510
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Events
Everyone Jonathan Kropski, MD
Yale Only Danielle Antin-Ozerkis, MD